These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10937611)

  • 1. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression.
    McGrath PJ; Stewart JW; Petkova E; Quitkin FM; Amsterdam JD; Fawcett J; Reimherr FW; Rosenbaum JF; Beasley CM
    J Clin Psychiatry; 2000 Jul; 61(7):518-24. PubMed ID: 10937611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.
    Schmidt ME; Fava M; Robinson JM; Judge R
    J Clin Psychiatry; 2000 Nov; 61(11):851-7. PubMed ID: 11105738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder.
    Dinan TG
    J Clin Psychiatry; 2001; 62 Suppl 22():48-52. PubMed ID: 11599649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of relapse in a prospective study of fluoxetine treatment of major depression.
    McGrath PJ; Stewart JW; Quitkin FM; Chen Y; Alpert JE; Nierenberg AA; Fava M; Cheng J; Petkova E
    Am J Psychiatry; 2006 Sep; 163(9):1542-8. PubMed ID: 16946178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.
    Yang H; Chuzi S; Sinicropi-Yao L; Johnson D; Chen Y; Clain A; Baer L; McGrath PJ; Stewart JW; Fava M; Papakostas GI
    Eur Arch Psychiatry Clin Neurosci; 2010 Mar; 260(2):145-50. PubMed ID: 19572158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy.
    Papakostas GI; Petersen T; Mischoulon D; Green CH; Nierenberg AA; Bottiglieri T; Rosenbaum JF; Alpert JE; Fava M
    J Clin Psychiatry; 2004 Aug; 65(8):1096-8. PubMed ID: 15323595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.
    Corya SA; Perlis RH; Keck PE; Lin DY; Case MG; Williamson DJ; Tohen MF
    J Clin Psychiatry; 2006 May; 67(5):798-806. PubMed ID: 16841630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
    Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
    J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When should a trial of fluoxetine for major depression be declared failed?
    Quitkin FM; Petkova E; McGrath PJ; Taylor B; Beasley C; Stewart J; Amsterdam J; Fava M; Rosenbaum J; Reimherr F; Fawcett J; Chen Y; Klein D
    Am J Psychiatry; 2003 Apr; 160(4):734-40. PubMed ID: 12668363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors and Moderators of Relapse in Children and Adolescents With Major Depressive Disorder.
    Kennard BD; Mayes TL; Chahal Z; Nakonezny PA; Moorehead A; Emslie GJ
    J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29474007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of onset of antidepressant response with fluoxetine treatment.
    Nierenberg AA; Farabaugh AH; Alpert JE; Gordon J; Worthington JJ; Rosenbaum JF; Fava M
    Am J Psychiatry; 2000 Sep; 157(9):1423-8. PubMed ID: 10964858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents.
    Emslie GJ; Kennard BD; Mayes TL; Nightingale-Teresi J; Carmody T; Hughes CW; Rush AJ; Tao R; Rintelmann JW
    Am J Psychiatry; 2008 Apr; 165(4):459-67. PubMed ID: 18281410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.
    Rosenbaum JF; Fava M; Hoog SL; Ascroft RC; Krebs WB
    Biol Psychiatry; 1998 Jul; 44(2):77-87. PubMed ID: 9646889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment.
    Reimherr FW; Amsterdam JD; Quitkin FM; Rosenbaum JF; Fava M; Zajecka J; Beasley CM; Michelson D; Roback P; Sundell K
    Am J Psychiatry; 1998 Sep; 155(9):1247-53. PubMed ID: 9734550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo.
    Stewart JW; Quitkin FM; McGrath PJ; Amsterdam J; Fava M; Fawcett J; Reimherr F; Rosenbaum J; Beasley C; Roback P
    Arch Gen Psychiatry; 1998 Apr; 55(4):334-43. PubMed ID: 9554429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder.
    de Klerk E
    J Clin Psychiatry; 2001; 62 Suppl 22():43-7. PubMed ID: 11599648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continued Effectiveness of Relapse Prevention Cognitive-Behavioral Therapy Following Fluoxetine Treatment in Youth With Major Depressive Disorder.
    Emslie GJ; Kennard BD; Mayes TL; Nakonezny PA; Moore J; Jones JM; Foxwell AA; King J
    J Am Acad Child Adolesc Psychiatry; 2015 Dec; 54(12):991-8. PubMed ID: 26598474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in adverse events reported by patients during 6 months of fluoxetine therapy.
    Zajecka J; Amsterdam JD; Quitkin FM; Reimherr FW; Rosenbaum JF; Tamura RN; Sundell KL; Michelson D; Beasley CM
    J Clin Psychiatry; 1999 Jun; 60(6):389-94. PubMed ID: 10401918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression.
    McGrath PJ; Stewart JW; Janal MN; Petkova E; Quitkin FM; Klein DF
    Am J Psychiatry; 2000 Mar; 157(3):344-50. PubMed ID: 10698808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
    Kornstein SG; Pedersen RD; Holland PJ; Nemeroff CB; Rothschild AJ; Thase ME; Trivedi MH; Ninan PT; Keller MB
    J Clin Psychiatry; 2014 Jan; 75(1):62-8. PubMed ID: 24345717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.